CalciMedica, Inc. — Director's Dealing 2020

Oct 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GRAYBUG VISION, INC. (GRAY)
CIK: 0001534133
Period of Report: 2020-09-29

Reporting Person: Flynn James E (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Mgmt HIF, L.P. (10% Owner, Possible Member of 10% Group)
Reporting Person: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Healthcare Innovations Fund, L.P. (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Mgmt L.P. (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Mgmt III, L.P. (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Private Design Fund III, L.P. (10% Owner, Possible Member of 10% Group)
Reporting Person: DEERFIELD PARTNERS, L.P. (10% Owner, Possible Member of 10% Group)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-29	Common Stock	C	1422406	—	Acquired	1422406	Indirect
2020-09-29	Common Stock	C	1422406	—	Acquired	1422406	Indirect
2020-09-29	Common Stock	C	291467	—	Acquired	1713873	Indirect
2020-09-29	Common Stock	C	291467	—	Acquired	1713873	Indirect
2020-09-29	Common Stock	C	291467	—	Acquired	291467	Indirect
2020-09-29	Common Stock	P	1562500	$16.00	Acquired	1853967	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-29	Series B Preferred Stock	$	C	12809912	Disposed		Common Stock (1422406)	Indirect
2020-09-29	Series B Preferred Stock	$	C	12809910	Disposed		Common Stock (1422406)	Indirect
2020-09-29	Series C Preferred Stock	$	C	2624901	Disposed		Common Stock (291467)	Indirect
2020-09-29	Series C Preferred Stock	$	C	2624901	Disposed		Common Stock (291467)	Indirect
2020-09-29	Series C Preferred Stock	$	C	2624901	Disposed		Common Stock (291467)	Indirect

Footnotes

F1: Each share of Series B Preferred Stock automatically converted into 0.11103955 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-9.0058 reverse stock split effected by the Issuer on September 18, 2020).

F2: Each share of Series C Preferred Stock automatically converted into 0.11103955 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-9.0058 reverse stock split effected by the Issuer on September 18, 2020).

F3: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund III and Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F4: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.